GRAFT-VERSUS-HOST DISEASE FOLLOWING TRANSPLANTATION OF ONE LOG VERSUS 2 LOG T-LYMPHOCYTE-DEPLETED BONE-MARROW FROM HLA-IDENTICAL DONORS
- 1 December 1986
- journal article
- research article
- Vol. 1 (2), 133-140
Abstract
Prevention of acute graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation, requires the depletion of mature T-lymphocytes from bone marrow grafts. The optimal degree of T-cell reduction is still an open question. We compared two procedures of T-cell separation in 18 consecutive recipients of genotypically HLA-matched bone marrow, who also received cyclosporin A for 6 months. The first method (A) was based on a discontinuous albumin gradient fractionation and resulted in an average T-lymphocyte content of 50 .times. 105/kg body weight (n = 9 patients); the second method (B) was based on E-rosette sedimentation and reduced the contamination to 15 .times. 104 grafted T-lymphocytes/kg body weight on the average (n = 9 patients). Thus, approximately 90 and 99% of the original T-lymphocytes were removed from the marrow grafts respectively. Of the seven patients of the first group who were at risk of GVHD (excluding two cases of early death), five developed a minimal-to-moderately severe acute GVHD and in two cases chronic GVHD ensued. Lethal GVHD was not seen. Of group B, all recipients engrafted and none developed GVHD (0/9). The difference in the frequency of GVHD between the two groups was highly significant (P < 0.0025). These data confirm our preclinical studies. They demonstrate that a one-log T-lymphocyte reduction of the marrow inoculum, when combined with cyclosporin A prophylaxis after major histocompatibility complex (MHC)-matched transplantation, is still associated with a considerable incidence of GVHD, whereas a two-log reduction of T-lymphocytes may provide full protection against acute GVHD.This publication has 13 references indexed in Scilit:
- Allogeneic bone marrow transplantation: the monitoring of granulocyte macrophage colonies following the collection of bone marrow mononuclear cells and after the subsequent in-vitro cytolysis of OKT3 positive lymphocytesBritish Journal of Haematology, 1983
- PRETREATMENT OF DONOR BONE MARROW WITH MONOCLONAL ANTIBODY OKT3 FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HISTOCOMPATIBLE BONE-MARROW TRANSPLANTATIONThe Lancet, 1982
- Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft-vs.-host disease by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin.The Journal of Experimental Medicine, 1982
- MARROW TRANSPLANTATION WITH OR WITHOUT DONOR BUFFY COAT CELLS FOR 65 TRANSFUSED APLASTIC-ANEMIA PATIENTS1982
- BONE MARROW TRANSPLANTATION ACROSS MAJOR HISTOCOMPATIBILITY BARRIERS IN MICE EFFECT OF ELIMINATION OF T CELLS FROM DONOR GRAFTS BY TREATMENT WITH MONOCLONAL THY-1.2 PLUS COMPLEMENT OR ANTIBODY ALONETransplantation, 1981
- Bone-Marrow Ablation and Allogeneic Marrow Transplantation in Acute LeukemiaNew England Journal of Medicine, 1980
- THE PLACE OF BONE-MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKÆMIAThe Lancet, 1980
- Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow GraftsNew England Journal of Medicine, 1979
- A methodological study of E-rosette formation using AET-treated sheep red blood cellsJournal of Immunological Methods, 1979
- Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins.Proceedings of the National Academy of Sciences, 1978